Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. (Q37802640)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

7

Julia M L Brotherton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

6

Lauri E Markowitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Charlene A Wong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mona Saraiya

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Susan Hariri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Linda Eckert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Roberta I Howlett

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Katy Sinka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Olga G Martinez-Montañez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Eileen F Dunne

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

5 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

878-885

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20971113%20AND%20SRC:MED&resulttype=core&format=json

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Chapter 15: HPV vaccine use in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Monitoring HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Post-licensure monitoring of HPV vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Evaluating the impact of human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

EUROGIN 2008 roadmap on cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

[Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The public health uses of the Scottish Community Health Index (CHI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Cervical cancer screening following prophylactic human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

7 January 2021

Editors' introduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The 2001 Bethesda System: terminology for reporting results of cervical cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The challenges of organising cervical screening programmes in the 15 old member states of the European Union

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Development and duration of human papillomavirus lesions, after initial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Epidemiology and costs associated with genital warts in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Contribution to the etiology of laryngeal papilloma in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Palliative aspects of recurrent respiratory papillomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Recurrent respiratory papillomatosis: update 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Recurrent respiratory papillomatosis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018

The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.018